JesusAngelMI Profile Banner
Jesús Ángel Martín Illán, PhD Profile
Jesús Ángel Martín Illán, PhD

@JesusAngelMI

Followers
144
Following
826
Media
15
Statuses
125

Biochemist | MA | #COFs

Madrid, Comunidad de Madrid
Joined March 2018
Don't wanna be here? Send us removal request.
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
1 year
RT @FrancescoSche20: TDXd can be reintroduced after G1 ILD and pts will gain benefit without any ILD recurrence in most cases. Don’t forge….
0
3
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
1 year
RT @DaiichiSankyoES: La Alianza #DaiichiSankyoES | @AstraZenecaES se ha unido hoy a la #MareaRosa de #Madrid para seguir visibilizando el #….
0
3
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @MamaCentro: Dra. Virginia Martínez : ¿Y si resulta que con los nuevos ADCs en CMA, no necesitamos saber el estado de ESR1 o PI3K?. #7No….
0
4
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @PTarantinoMD: Quite encouraging activity (ORR 30%) of T-DXd across ERBB2-mutant tumors (#DPT01)- yet interesting to see even more enhan….
0
25
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
Finding the positive in the TNBC #ESMO2023 #breastcancer @evaciruelos
Tweet media one
0
0
4
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @PTarantinoMD: After being announced to be positive, the TROPION-Breast01 phase 3 trial officially joins the already stellar list of abs….
0
27
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @COF_papers: Evolution of covalent organic frameworks: From design to real-world applications
0
2
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @PTarantinoMD: Among the most thought-provoking posters of #AACR23: Revisiting the Dogma of ADCs, by @Raffaele_1985 & colleagues. Many i….
0
11
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @PTarantinoMD: Impressive waterfall plots for SHR-A1811 in HER2+ and HER2-low MBC. Responses observed at all dose levels and in patients….
0
41
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
101 citations 💪🏼💪🏼 #COFs .
0
0
12
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @drsarahsam: Presenting our RWD case series describing activity of TDXd in heavily pretreated HER2+ Leptomeningeal Metastases. Formal….
Tweet card summary image
nature.com
npj Breast Cancer - Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
0
22
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @tompowles1: Pfizer’s acquisition of Seagen will have an impact on drug development in UC. EV/pembro’s potential move into the 1st line….
0
8
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @DaiichiSankyoES: Besos, abrazos, caricias… son importantes hoy y todos los días. Y más para las personas con #cáncer. En #DaiichiSankyo….
0
2
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
RT @MAmbBioquimUCLM: Enhorabuena a nuestro egresado @JesusAngelMI por su tesis doctoral.
0
2
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
Y por supuesto a @fzamora0 por hacer de esta tesis no solo algo gratificante si no también divertido. (2/2)
Tweet media one
0
1
18
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
2 years
El pasado jueves cerré una etapa con la defensa de mi tesis doctoral. Una etapa bonita tanto en lo personal como en lo profesional. Agradecer a mi extraordinario tribunal @MaraMontoro @KokeLab @GMinguezEsp su participación en este broche final. (1/2).
3
0
23
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
3 years
RT @Nature: FDA approves Alzheimer’s drug lecanemab amid safety concerns
0
27
0
@JesusAngelMI
Jesús Ángel Martín Illán, PhD
3 years
RT @ECSalud_com: #Internacional | @DaiichiSankyo presentará los avances y resultados de sus anticuerpos conjugados en el Simposio de #Cánce….
0
1
0